A Spanish startup has become one of only four companies authorised by Spain’s medicines regulator to cultivate medical cannabis, positioning itself to supply export markets in the UK and Germany from a pharmaceutical-grade indoor facility in the Ribera region of Burgos.
Cannabis remained Europe’s most commonly used drug in 2025, according to new wastewater analysis from the European Union Drugs Agency (EUDA), suggesting around 8.4% of European adults have consumed cannabis within the last year.
It’s now five months since the German Federal Cabinet adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) bill, and its finalisation is expected in the coming weeks.
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower in 2025, a 12% increase from the prior year, according to new data obtained by Prohibition Partners.
Today (February 19, 2026), Cannabis Europa returns to the French capital for the first time since 2019 at a critical juncture for the incoming French medical cannabis industry.
As Europe’s medical cannabis markets continue to mature, an increasingly familiar pattern is beginning to emerge.
Last year, as other European cannabis markets looked to be retreating from their ambitious progress in 2024, Switzerland accelerated its plans for cannabis reform.
Earlier this week (Tuesday, January 27), France’s government survived two no-confidence votes, finally passing its contentious 2026 budget following months of political crisis that had largely paralysed non-urgent policymaking.
